[go: up one dir, main page]

MX2013010796A - Combinaciones que comprenden brezipirrazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central. - Google Patents

Combinaciones que comprenden brezipirrazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central.

Info

Publication number
MX2013010796A
MX2013010796A MX2013010796A MX2013010796A MX2013010796A MX 2013010796 A MX2013010796 A MX 2013010796A MX 2013010796 A MX2013010796 A MX 2013010796A MX 2013010796 A MX2013010796 A MX 2013010796A MX 2013010796 A MX2013010796 A MX 2013010796A
Authority
MX
Mexico
Prior art keywords
drug
salt
reuptake inhibitor
antidepressant
brexpiprazole
Prior art date
Application number
MX2013010796A
Other languages
English (en)
Other versions
MX370670B (es
Inventor
Tsuyoshi Hirose
Kenji Maeda
Tetsuro Kikuchi
Masafumi Toda
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46045045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013010796(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2013010796A publication Critical patent/MX2013010796A/es
Publication of MX370670B publication Critical patent/MX370670B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un medicamento que tiene un mayor espectro de tratamiento, causando menores efectos colaterales y que es superior en tolerabilidad y seguridad, en comparación con agentes antipsicóticos típicos y agentes antipsicóticos atípicos conocidos. La presente invención se refiere a un medicamento que contiene (I) un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1H-quinolin-2- ona o una de sus sales y (II) al menos un fármaco seleccionado del grupo que consiste en un estabilizador del estado de ánimo, un inhibidor de la reabsorción de serotonina, un inhibidor de la reabsorción de norepinefrina, un inhibidor de la reabsorción de serotonina y norepinefrina, un antidepresivo noradrenérgico y serotonérgico específico, un fármaco antiansiedad, un antidepresivo tricíclico, un antidepresivo tetracíclico, un fármaco antipsicótico y un fármaco anti-ADHD, en combinación.
MX2013010796A 2011-04-05 2012-04-04 Combinaciones que comprenden brexipiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central. MX370670B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161471911P 2011-04-05 2011-04-05
US201161580540P 2011-12-27 2011-12-27
PCT/JP2012/059825 WO2012137971A1 (en) 2011-04-05 2012-04-04 Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder

Publications (2)

Publication Number Publication Date
MX2013010796A true MX2013010796A (es) 2013-12-06
MX370670B MX370670B (es) 2019-12-19

Family

ID=46045045

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013010796A MX370670B (es) 2011-04-05 2012-04-04 Combinaciones que comprenden brexipiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central.
MX2019015237A MX390286B (es) 2011-04-05 2012-04-04 Combinaciones que comprenden brexpiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019015237A MX390286B (es) 2011-04-05 2012-04-04 Combinaciones que comprenden brexpiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central.

Country Status (33)

Country Link
US (7) US20140120185A1 (es)
EP (5) EP3626243A1 (es)
JP (2) JP5992924B2 (es)
KR (1) KR101890450B1 (es)
CN (2) CN103547260B (es)
AR (1) AR085840A1 (es)
AU (1) AU2012240864B2 (es)
BR (1) BR112013025420B1 (es)
CA (1) CA2832157C (es)
CO (1) CO6801769A2 (es)
CY (1) CY1120567T1 (es)
DK (1) DK2694043T3 (es)
EA (1) EA035837B1 (es)
ES (1) ES2654851T3 (es)
HK (1) HK1246159A1 (es)
HR (1) HRP20180098T1 (es)
HU (1) HUE035542T2 (es)
IL (1) IL228669B (es)
JO (2) JOP20120083B1 (es)
LT (1) LT2694043T (es)
MX (2) MX370670B (es)
MY (1) MY166936A (es)
NZ (1) NZ615591A (es)
PH (3) PH12020500280A1 (es)
PL (1) PL2694043T3 (es)
PT (1) PT2694043T (es)
RS (1) RS56802B1 (es)
SG (2) SG10201602326RA (es)
SI (1) SI2694043T1 (es)
SM (1) SMT201800033T1 (es)
TW (1) TWI636784B (es)
WO (1) WO2012137971A1 (es)
ZA (1) ZA201306981B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
TWI679977B (zh) * 2011-10-19 2019-12-21 大塚製藥股份有限公司 口服溶液
TW201332572A (zh) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JOP20210047A1 (ar) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
EP3827820A1 (en) * 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
JP6797691B2 (ja) 2014-04-22 2020-12-09 大塚製薬株式会社 ブレクスピプラゾールとナルメフェンの組み合わせ剤及び物質関連障害を治療するためのその用途
CA2951072A1 (en) * 2014-06-06 2015-12-10 Rhodes Pharmaceuticals, L.P. Methods for treating attention deficit hyperactivity disorder with methylphenidate
CA2936740C (en) 2014-10-31 2017-10-10 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
AU2017240259A1 (en) 2016-04-01 2018-10-18 Upmc Regulatory device and associated method
US11123300B2 (en) 2016-08-16 2021-09-21 Hexal Ag Immediate release tablet of a benzothiophene compound
WO2018033484A1 (en) 2016-08-16 2018-02-22 Hexal Aktiengesellschaft Pharmaceutical compositions of a benzothiophene compound
HUE050403T2 (hu) * 2016-10-28 2020-12-28 H Lundbeck As Imidazopirazinonokkal végzett kombinációs kezelések pszichiátriai és/vagy kognitív betegségek kezelésére
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
EP3501506B1 (en) * 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
JP2019183095A (ja) * 2018-08-16 2019-10-24 株式会社Ｄｎｐファインケミカル 接着性粉体、接着性錠剤の製造方法、接着性錠剤、並びに該接着性粉体及び錠剤を用いた部材又は部品の製造方法
JP6831354B2 (ja) * 2018-08-16 2021-02-17 株式会社Ｄｎｐファインケミカル 接着性組成物からなる錠剤、その製造方法、及び該錠剤を用いた部材又は部品の製造方法
US12138363B2 (en) * 2018-10-04 2024-11-12 École Polytechnique Fédérale de Lausanne Cross-linkable polymer, hydrogel, and method of preparation thereof
KR20210102211A (ko) * 2018-10-24 2021-08-19 이펙터 테라퓨틱스, 인크. Mnk 억제제의 결정질 형태
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN113993523A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗抑郁症和其他各种病症
WO2021029020A1 (ja) * 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
CN113322299A (zh) * 2021-05-28 2021-08-31 南昌大学 一种抑郁症和药物成瘾疾病的药物靶点识别方法
CN116407539B (zh) * 2021-12-30 2025-01-10 上海现代药物制剂工程研究中心有限公司 依匹哌唑甲基脂肪酸酯的用途
US20240009181A1 (en) * 2022-07-08 2024-01-11 Jason Eric Schiffman Method for the treatment and prophylaxis of substance-related and/or addictive disorders including substance/medication-induced depressive disorders, bipolar and related disorders, and anxiety disorders and compositions useful for the same
FR3142667A1 (fr) * 2022-12-01 2024-06-07 Capsum Composition solide non pulvérulente comprenant au moins 8% en poids d’agent(s) désintégrant
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
TR2023018024A1 (tr) * 2023-12-22 2025-07-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Brekspi̇prazol i̇çeren tabletler
TR2023018022A1 (tr) * 2023-12-22 2025-07-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Brekspi̇prazol i̇çeren bi̇r tablet

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL123716A (en) * 1997-03-27 2001-03-19 Akzo Nobel Nv Therapeutic combinations of mirtazapine and an antipsychotic agent
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US20040176466A1 (en) * 2001-08-08 2004-09-09 Allen Albert John Combination therapy for the treatment of neurological disorders
WO2004060374A1 (en) * 2002-12-27 2004-07-22 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
JP2008504295A (ja) * 2004-06-25 2008-02-14 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム 注意欠陥多動性障害及び高フェニルアラニン血症の治療のための方法及び組成物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
EP2089015B1 (en) * 2006-10-27 2010-11-24 Janssen Pharmaceutica, N.V. Methods for treating disruptive behavior disorders
JP2008189616A (ja) * 2007-02-07 2008-08-21 Mitsubishi Tanabe Pharma Corp 注意欠陥多動性障害の治療薬
JP2011136906A (ja) * 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物

Also Published As

Publication number Publication date
IL228669B (en) 2020-04-30
US20180325894A1 (en) 2018-11-15
JOP20120083B1 (ar) 2021-08-17
US20250177385A1 (en) 2025-06-05
LT2694043T (lt) 2018-02-12
US20170100395A1 (en) 2017-04-13
BR112013025420A2 (pt) 2016-12-27
EA035837B1 (ru) 2020-08-19
PT2694043T (pt) 2018-01-16
EP3626243A1 (en) 2020-03-25
WO2012137971A1 (en) 2012-10-11
EP2694043B1 (en) 2017-11-01
SG193468A1 (en) 2013-10-30
MX2019015237A (es) 2020-02-13
PH12020552079A1 (en) 2023-05-31
AU2012240864A1 (en) 2013-11-07
US20240156811A1 (en) 2024-05-16
ZA201306981B (en) 2014-05-28
JP2017031155A (ja) 2017-02-09
PH12013501908A1 (en) 2013-11-25
TWI636784B (zh) 2018-10-01
HRP20180098T1 (hr) 2018-03-23
SG10201602326RA (en) 2016-04-28
CN108042808B (zh) 2021-02-09
HUE035542T2 (hu) 2018-05-02
PH12020500280A1 (en) 2022-03-21
KR20140021648A (ko) 2014-02-20
BR112013025420B1 (pt) 2021-10-13
SMT201800033T1 (it) 2018-03-08
EP4570250A2 (en) 2025-06-18
CN103547260A (zh) 2014-01-29
DK2694043T3 (en) 2018-01-15
US20140120185A1 (en) 2014-05-01
JP2014510023A (ja) 2014-04-24
MY166936A (en) 2018-07-25
CN108042808A (zh) 2018-05-18
RS56802B1 (sr) 2018-04-30
EP4570250A3 (en) 2025-08-27
AR085840A1 (es) 2013-10-30
MX370670B (es) 2019-12-19
CA2832157A1 (en) 2012-10-11
CY1120567T1 (el) 2019-07-10
JOP20210035A1 (ar) 2023-01-30
EP4023223A1 (en) 2022-07-06
SI2694043T1 (en) 2018-03-30
US20180042923A1 (en) 2018-02-15
EA201391450A1 (ru) 2014-03-31
CA2832157C (en) 2023-06-27
AU2012240864B2 (en) 2017-02-02
ES2654851T3 (es) 2018-02-15
MX390286B (es) 2025-03-20
EP3299018A1 (en) 2018-03-28
NZ615591A (en) 2016-02-26
IL228669A0 (en) 2013-12-31
EP2694043A1 (en) 2014-02-12
CO6801769A2 (es) 2013-11-29
HK1246159A1 (en) 2018-09-07
CN103547260B (zh) 2019-08-13
KR101890450B1 (ko) 2018-08-21
PL2694043T3 (pl) 2018-04-30
TW201311242A (zh) 2013-03-16
JP5992924B2 (ja) 2016-09-14
US20220000861A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
JOP20210035A1 (ar) توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
EA201171493A1 (ru) МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК
MX2015012867A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
JOP20130313B1 (ar) عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
SG195106A1 (en) Trpv4 antagonists
DOP2009000232A (es) Metanoisoindoles y dionas de éstos como agentes anti-psicóticos.
MA32784B1 (fr) Composes aryles substitues par heterocycle comme inhibiteurs de hif
JO3148B1 (ar) مركب مثبط لإشارات مسار notch
EA201170997A1 (ru) Производные индола в качестве противораковых агентов
EA201171172A1 (ru) Применение в терапии производных хиназолиндиона
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
EP2416795A4 (en) COGNITIVE DECLINE INHIBITORS
NI201000176A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
UA104880C2 (uk) Заміщені тетрагідропіранспіропіролідинон і тетрагідропіранспіропіперидинон, спосіб їх одержання й застосування в лікувальних цілях
EA200970849A1 (ru) Трициклические производные изохинолина для лечения ожирения
EA201270556A1 (ru) Конденсированные тиазоло и оксазолопиримидиноны
MX2012007253A (es) Derivados triciclicos y sus usos y composiciones farmaceuticas.
DE602008002598D1 (en) Cyclohexylderivate
MX2010004314A (es) Compuestos para inhibir la actividad de quinesina de la proteina quinesina del huso.
MX2010004315A (es) Compuestos para inhibir la actividad de quinesina ksp.
TH151403A (th) ตัวยารวมซึ่งประกอบรวมด้วยเบรกซ์พิแพรโซลหรือเกลือของสารนั้น และยาชนิดที่สองสำหรับใช้ในการรักษาโรคของ cns
GEP201706657B (en) Quinoline derivatives as pde10a enzyme inhibitors
MX2011007897A (es) Derivados de sulfamoil-fenil-ureido benzamidina como agentes contra la malaria.
EA200802000A1 (ru) Фармацевтически приемлемые соли и полиморфные формы

Legal Events

Date Code Title Description
FG Grant or registration